<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04487652</url>
  </required_header>
  <id_info>
    <org_study_id>2019-01542</org_study_id>
    <nct_id>NCT04487652</nct_id>
  </id_info>
  <brief_title>Ubiquinone (Coenzyme Q10) Application After Gingival Recession Coverage</brief_title>
  <official_title>Effect of Ubiquinone (Coenzyme Q10) on Early Wound Healing Following Gingival Recession Coverage: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Bern</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Bern</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomised double blinded clinical trial has the aim to assess the effect of ubiquinone&#xD;
      (Coenzyme Q10) on early wound healing following gingival recession coverage. Coenzyme Q10&#xD;
      (CoQ10) is a critical intermediate of the mitochondrial electron transport chain for the&#xD;
      synthesis of adenosine triphosphate. The biological importance of CoQ10 is related to&#xD;
      antioxidant activity, which can scavenge free radicals as well as restore the antioxidant&#xD;
      defence system. Both in vitro and animal studies have suggested that CoQ10 acts as&#xD;
      anti-inflammatory agent reducing the inflammatory response by inhibiting the translocation of&#xD;
      nuclear factor kappa beta into the nucleus.&#xD;
&#xD;
      Gingival recessions particularly in the esthetic area have become a common indication for&#xD;
      treatment. The use of subepithelial palatal connective tissue graft (SCTG) in conjunction&#xD;
      with either a coronally advanced flap (CAF) or a coronally advanced tunnel are well&#xD;
      established techniques for both the treatment of single and multiple gingival recessions.&#xD;
&#xD;
      Interestingly, despite the fact that CoQ10 is widely investigated, virtually no information&#xD;
      exists on its effects upon early wound healing of oral tissues. Therefore, the aim of this&#xD;
      study is to investigate the effect of CoQ10 on wound healing after gingival recession&#xD;
      surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gingival recessions constitute a common problem in the adult population worldwide. In the&#xD;
      United States the prevalence of ≥1 mm recession in persons &gt;30 years was 58%, representing&#xD;
      over 60 million adults while in a French cohort aged 30-65 years old 84.6% had at least one&#xD;
      gingival recession. In two other studies it has been reported that over 90% of adults aged 35&#xD;
      to 50 years and above present with single or multiple gingival recessions. The consequences&#xD;
      of gingival recessions can be gingivitis due to suboptimal oral hygiene, tooth mobility and&#xD;
      in extreme circumstances tooth loss. Tooth sensitivity, root caries, non-carious cervical&#xD;
      lesions and esthetic concerns especially with anteriorly located recessions can be also&#xD;
      encountered. With the yearly increase in the number of orthodontic patients a potentially&#xD;
      additional burden is expected in the population.&#xD;
&#xD;
      The use of subepithelial palatal connective tissue graft (SCTG) in conjunction with either&#xD;
      coronally advanced flap (CAF) or coronally advanced tunnel are well established techniques&#xD;
      for the treatment of single and multiple gingival recessions. These techniques have been&#xD;
      shown to result in predictable root coverage, higher increase in keratinized tissue and&#xD;
      stable long-term outcomes thus being considered today state of the art.&#xD;
&#xD;
      Coenzyme Q10 (CoQ10), referred to as 'ubiquinone', is endogenously synthesised by the&#xD;
      mevalonate pathway in the human body and is obtained in much of human diet. CoQ10 is a&#xD;
      critical intermediate of the mitochondrial electron transport chain for the synthesis of&#xD;
      adenosine triphosphate. The biological importance of CoQ10 is related to antioxidant&#xD;
      activity, which can scavenge free radicals as well as restore the antioxidant defence system.&#xD;
      Furthermore, in vitro and animal studies have suggested that CoQ10 acts as anti-inflammatory&#xD;
      agent reducing the inflammatory response by inhibiting the translocation of nuclear factor&#xD;
      kappa beta into the nucleus. Owing to its anti-oxidative and anti-inflammatory capacities&#xD;
      CoQ10 is of potential therapeutic value in numerous chronic diseases including periodontitis,&#xD;
      rheumatoid arthritis or cardiovascular disease. Moreover, it might exert also beneficial&#xD;
      effects on wound healing by reducing inflammation and oxidative stress. A recent clinical&#xD;
      trial showed that the serum level of TNF-α was significantly reduced in patients with&#xD;
      rheumatoid arthritis who received capsules of CoQ10 (100mg/day) for 8 weeks. However, to&#xD;
      date, no published study has investigated the anti-oxidative and anti-inflammation effects of&#xD;
      coenzyme Q10 spray on oral wound healing. Thus, the purpose of this clinical study is to&#xD;
      examine the early wound healing after coenzyme Q10 spray administration (for 3 weeks) in&#xD;
      patients undergoing recession coverage surgery.&#xD;
&#xD;
      For this pilot study 30 patients exhibiting single or multiple gingival recessions (Miller&#xD;
      class I-III) will randomly be assigned to the control or test group and will be using a&#xD;
      placebo or CoQ10 spray for 3 weeks. The primary endpoint is:&#xD;
&#xD;
      • the progress of wound healing assessed by the early wound healing index EHI previously&#xD;
      defined by Wachtel et al. 2003.&#xD;
&#xD;
      The secondary endpoints are:&#xD;
&#xD;
        -  the improvement of patients' postoperative comfort see patient questionnaire (VAS scale)&#xD;
&#xD;
        -  the percentage of root coverage after 6 months&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Actual">January 31, 2023</completion_date>
  <primary_completion_date type="Actual">August 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomised placebo-controlled, double blinded, mono-centric trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Early wound healing assessed by the early wound healing index by Wachtel</measure>
    <time_frame>assessed 2 days after surgery</time_frame>
    <description>The early wound healing index by Wachtel describes 5 different stages of wound healing from no fibrin coverage until pus formation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Early wound healing assessed by the early wound healing index by Wachtel</measure>
    <time_frame>assessed 7 days after surgery</time_frame>
    <description>The early wound healing index by Wachtel describes 5 different stages of wound healing from no fibrin coverage until pus formation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Early wound healing assessed by the early wound healing index by Wachtel</measure>
    <time_frame>assessed 14 days after surgery</time_frame>
    <description>The early wound healing index by Wachtel describes 5 different stages of wound healing from no fibrin coverage until pus formation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Early wound healing assessed by the early wound healing index by Wachtel</measure>
    <time_frame>assessed 21 days after surgery</time_frame>
    <description>The early wound healing index by Wachtel describes 5 different stages of wound healing from no fibrin coverage until pus formation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>VAS scale</measure>
    <time_frame>2 days until 21 days postoperatively</time_frame>
    <description>The patients'postoperative pain level, 1000 mm scale with 0 representing &quot;no pain&quot; and 1000 mm representing &quot;maximal pain&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of root coverage</measure>
    <time_frame>6 months postoperatively</time_frame>
    <description>How much expressed in percentage of the baseline recession is covered after 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase of Keratinized tissue</measure>
    <time_frame>6 months postoperatively</time_frame>
    <description>How much keratinized tissue has been gained</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Esthetic outcome</measure>
    <time_frame>6 months postoperatively</time_frame>
    <description>Esthetic outcomes will be assessed by the root coverage esthetic score, established by Cairo et al. 2009. Parameters like gingival texture, full coverage, marginal tissue contour, scar tissue are evaluated. The maximal score is 10.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Gingival Recession</condition>
  <arm_group>
    <arm_group_label>Placebo spray</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Spray consists of matrix out of water, phospholipids and glycerine, plus coloration Colour Sunset Yello E 110 to mimic the test spray</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CoQ10 spray</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The CoQ10 spray contains a high quality Kaneka A10 containing CoQ10 trans-isomers which is embedded in a matrix out of water, phospholipids and glycerine. Adana Pharma GmbH is processing the CoQ10 substance into the matrix. One application contains 7 mg CoQ10.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Gingival recession coverage</intervention_name>
    <description>The Modified Coronally Advanced Tunnel technique in conjunction with a palatal subepithelial connective tissue graft will be performed.</description>
    <arm_group_label>CoQ10 spray</arm_group_label>
    <arm_group_label>Placebo spray</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>with CoQ10 spray application</intervention_name>
    <description>After surgical recession coverage a CoQ10 spray will be applied during the early phase of wound healing.</description>
    <arm_group_label>CoQ10 spray</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>with placebo spray application</intervention_name>
    <description>After surgical recession coverage a placebo spray will be applied during the early phase of wound healing.</description>
    <arm_group_label>Placebo spray</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with single and multiple Miller class I, II and III gingival recessions will&#xD;
             be included&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a history of chronic inflammatory disease&#xD;
&#xD;
          -  Patients with severe systemic diseases&#xD;
&#xD;
          -  Patients with any sign of clinical infection&#xD;
&#xD;
          -  Patients smoking &gt; 5 cigarettes&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Patients &lt; 18 years of age&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anton Sculean, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Bern</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Periodontology</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Lanzrein C, Guldener K, Imber JC, Katsaros C, Stahli A, Sculean A. Treatment of multiple adjacent recessions with the modified coronally advanced tunnel or laterally closed tunnel in conjunction with cross-linked hyaluronic acid and subepithelial connective tissue graft: a report of 15 cases. Quintessence Int. 2020;51(9):710-719. doi: 10.3290/j.qi.a44808.</citation>
    <PMID>32577705</PMID>
  </reference>
  <reference>
    <citation>Guldener K, Lanzrein C, Eliezer M, Katsaros C, Stahli A, Sculean A. Treatment of single mandibular recessions with the modified coronally advanced tunnel or laterally closed tunnel, hyaluronic acid, and subepithelial connective tissue graft: a report of 12 cases. Quintessence Int. 2020;51(6):456-463. doi: 10.3290/j.qi.a44492.</citation>
    <PMID>32368762</PMID>
  </reference>
  <reference>
    <citation>Liu HT, Huang YC, Cheng SB, Huang YT, Lin PT. Effects of coenzyme Q10 supplementation on antioxidant capacity and inflammation in hepatocellular carcinoma patients after surgery: a randomized, placebo-controlled trial. Nutr J. 2016 Oct 6;15(1):85. doi: 10.1186/s12937-016-0205-6.</citation>
    <PMID>27716246</PMID>
  </reference>
  <reference>
    <citation>Sahebkar A, Simental-Mendia LE, Stefanutti C, Pirro M. Supplementation with coenzyme Q10 reduces plasma lipoprotein(a) concentrations but not other lipid indices: A systematic review and meta-analysis. Pharmacol Res. 2016 Mar;105:198-209. doi: 10.1016/j.phrs.2016.01.030. Epub 2016 Feb 2.</citation>
    <PMID>26836888</PMID>
  </reference>
  <reference>
    <citation>Alam MA, Rahman MM. Mitochondrial dysfunction in obesity: potential benefit and mechanism of Co-enzyme Q10 supplementation in metabolic syndrome. J Diabetes Metab Disord. 2014 May 23;13:60. doi: 10.1186/2251-6581-13-60. eCollection 2014.</citation>
    <PMID>24932457</PMID>
  </reference>
  <results_reference>
    <citation>Stahli A, Imber JC, Raptis E, Salvi GE, Eick S, Sculean A. Effect of enamel matrix derivative on wound healing following gingival recession coverage using the modified coronally advanced tunnel and subepithelial connective tissue graft: a randomised, controlled, clinical study. Clin Oral Investig. 2020 Feb;24(2):1043-1051. doi: 10.1007/s00784-019-03008-6. Epub 2019 Jul 9.</citation>
    <PMID>31290017</PMID>
  </results_reference>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>July 22, 2020</study_first_submitted>
  <study_first_submitted_qc>July 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2020</study_first_posted>
  <last_update_submitted>March 22, 2023</last_update_submitted>
  <last_update_submitted_qc>March 22, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gingival Recession</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coenzyme Q10</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Upon request the individual participant data will be shared</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04487652
org study id: 2019-01542
nct id: NCT04487652
lead sponsor: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
This randomised double blinded clinical trial has the aim to assess the effect of ubiquinone
      (Coenzyme Q10) on early wound healing following gingival recession coverage. Coenzyme Q10
      (CoQ10) is a critical intermediate of the mitochondrial electron transport chain for the
      synthesis of adenosine triphosphate. The biological importance of CoQ10 is related to
      antioxidant activity, which can scavenge free radicals as well as restore the antioxidant
      defence system. Both in vitro and animal studies have suggested that CoQ10 acts as
      anti-inflammatory agent reducing the inflammatory response by inhibiting the translocation of
      nuclear factor kappa beta into the nucleus.

      Gingival recessions particularly in the esthetic area have become a common indication for
      treatment. The use of subepithelial palatal connective tissue graft (SCTG) in conjunction
      with either a coronally advanced flap (CAF) or a coronally advanced tunnel are well
      established techniques for both the treatment of single and multiple gingival recessions.

      Interestingly, despite the fact that CoQ10 is widely investigated, virtually no information
      exists on its effects upon early wound healing of oral tissues. Therefore, the aim of this
      study is to investigate the effect of CoQ10 on wound healing after gingival recession
      surgery.
Gingival recessions constitute a common problem in the adult population worldwide. In the
      United States the prevalence of ≥1 mm recession in persons >30 years was 58%, representing
      over 60 million adults while in a French cohort aged 30-65 years old 84.6% had at least one
      gingival recession. In two other studies it has been reported that over 90% of adults aged 35
      to 50 years and above present with single or multiple gingival recessions. The consequences
      of gingival recessions can be gingivitis due to suboptimal oral hygiene, tooth mobility and
      in extreme circumstances tooth loss. Tooth sensitivity, root caries, non-carious cervical
      lesions and esthetic concerns especially with anteriorly located recessions can be also
      encountered. With the yearly increase in the number of orthodontic patients a potentially
      additional burden is expected in the population.

      The use of subepithelial palatal connective tissue graft (SCTG) in conjunction with either
      coronally advanced flap (CAF) or coronally advanced tunnel are well established techniques
      for the treatment of single and multiple gingival recessions. These techniques have been
      shown to result in predictable root coverage, higher increase in keratinized tissue and
      stable long-term outcomes thus being considered today state of the art.

      Coenzyme Q10 (CoQ10), referred to as 'ubiquinone', is endogenously synthesised by the
      mevalonate pathway in the human body and is obtained in much of human diet. CoQ10 is a
      critical intermediate of the mitochondrial electron transport chain for the synthesis of
      adenosine triphosphate. The biological importance of CoQ10 is related to antioxidant
      activity, which can scavenge free radicals as well as restore the antioxidant defence system.
      Furthermore, in vitro and animal studies have suggested that CoQ10 acts as anti-inflammatory
      agent reducing the inflammatory response by inhibiting the translocation of nuclear factor
      kappa beta into the nucleus. Owing to its anti-oxidative and anti-inflammatory capacities
      CoQ10 is of potential therapeutic value in numerous chronic diseases including periodontitis,
      rheumatoid arthritis or cardiovascular disease. Moreover, it might exert also beneficial
      effects on wound healing by reducing inflammation and oxidative stress. A recent clinical
      trial showed that the serum level of TNF-α was significantly reduced in patients with
      rheumatoid arthritis who received capsules of CoQ10 (100mg/day) for 8 weeks. However, to
      date, no published study has investigated the anti-oxidative and anti-inflammation effects of
      coenzyme Q10 spray on oral wound healing. Thus, the purpose of this clinical study is to
      examine the early wound healing after coenzyme Q10 spray administration (for 3 weeks) in
      patients undergoing recession coverage surgery.

      For this pilot study 30 patients exhibiting single or multiple gingival recessions (Miller
      class I-III) will randomly be assigned to the control or test group and will be using a
      placebo or CoQ10 spray for 3 weeks. The primary endpoint is:

      • the progress of wound healing assessed by the early wound healing index EHI previously
      defined by Wachtel et al. 2003.

      The secondary endpoints are:

        -  the improvement of patients' postoperative comfort see patient questionnaire (VAS scale)

        -  the percentage of root coverage after 6 months
allocation: Randomized
intervention model: Parallel Assignment
intervention model description: Randomised placebo-controlled, double blinded, mono-centric trial
primary purpose: Treatment
masking: Double (Participant, Outcomes Assessor)
measure: Early wound healing assessed by the early wound healing index by Wachtel
time frame: assessed 2 days after surgery
description: The early wound healing index by Wachtel describes 5 different stages of wound healing from no fibrin coverage until pus formation.
measure: Early wound healing assessed by the early wound healing index by Wachtel
time frame: assessed 7 days after surgery
description: The early wound healing index by Wachtel describes 5 different stages of wound healing from no fibrin coverage until pus formation.
measure: Early wound healing assessed by the early wound healing index by Wachtel
time frame: assessed 14 days after surgery
description: The early wound healing index by Wachtel describes 5 different stages of wound healing from no fibrin coverage until pus formation.
measure: Early wound healing assessed by the early wound healing index by Wachtel
time frame: assessed 21 days after surgery
description: The early wound healing index by Wachtel describes 5 different stages of wound healing from no fibrin coverage until pus formation.
measure: VAS scale
time frame: 2 days until 21 days postoperatively
description: The patients'postoperative pain level, 1000 mm scale with 0 representing "no pain" and 1000 mm representing "maximal pain"
measure: Percentage of root coverage
time frame: 6 months postoperatively
description: How much expressed in percentage of the baseline recession is covered after 6 months
measure: Increase of Keratinized tissue
time frame: 6 months postoperatively
description: How much keratinized tissue has been gained
measure: Esthetic outcome
time frame: 6 months postoperatively
description: Esthetic outcomes will be assessed by the root coverage esthetic score, established by Cairo et al. 2009. Parameters like gingival texture, full coverage, marginal tissue contour, scar tissue are evaluated. The maximal score is 10.
arm group label: Placebo spray
arm group type: Placebo Comparator
description: Spray consists of matrix out of water, phospholipids and glycerine, plus coloration Colour Sunset Yello E 110 to mimic the test spray
arm group label: CoQ10 spray
arm group type: Experimental
description: The CoQ10 spray contains a high quality Kaneka A10 containing CoQ10 trans-isomers which is embedded in a matrix out of water, phospholipids and glycerine. Adana Pharma GmbH is processing the CoQ10 substance into the matrix. One application contains 7 mg CoQ10.
intervention type: Other
intervention name: Gingival recession coverage
description: The Modified Coronally Advanced Tunnel technique in conjunction with a palatal subepithelial connective tissue graft will be performed.
arm group label: CoQ10 spray
arm group label: Placebo spray
intervention type: Drug
intervention name: with CoQ10 spray application
description: After surgical recession coverage a CoQ10 spray will be applied during the early phase of wound healing.
arm group label: CoQ10 spray
intervention type: Drug
intervention name: with placebo spray application
description: After surgical recession coverage a placebo spray will be applied during the early phase of wound healing.
arm group label: Placebo spray
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: Accepts Healthy Volunteers
last name: Anton Sculean, Prof.
role: Principal Investigator
affiliation: University of Bern
facility: 
country: Switzerland
citation: Lanzrein C, Guldener K, Imber JC, Katsaros C, Stahli A, Sculean A. Treatment of multiple adjacent recessions with the modified coronally advanced tunnel or laterally closed tunnel in conjunction with cross-linked hyaluronic acid and subepithelial connective tissue graft: a report of 15 cases. Quintessence Int. 2020;51(9):710-719. doi: 10.3290/j.qi.a44808.
PMID: 32577705
citation: Guldener K, Lanzrein C, Eliezer M, Katsaros C, Stahli A, Sculean A. Treatment of single mandibular recessions with the modified coronally advanced tunnel or laterally closed tunnel, hyaluronic acid, and subepithelial connective tissue graft: a report of 12 cases. Quintessence Int. 2020;51(6):456-463. doi: 10.3290/j.qi.a44492.
PMID: 32368762
citation: Liu HT, Huang YC, Cheng SB, Huang YT, Lin PT. Effects of coenzyme Q10 supplementation on antioxidant capacity and inflammation in hepatocellular carcinoma patients after surgery: a randomized, placebo-controlled trial. Nutr J. 2016 Oct 6;15(1):85. doi: 10.1186/s12937-016-0205-6.
PMID: 27716246
citation: Sahebkar A, Simental-Mendia LE, Stefanutti C, Pirro M. Supplementation with coenzyme Q10 reduces plasma lipoprotein(a) concentrations but not other lipid indices: A systematic review and meta-analysis. Pharmacol Res. 2016 Mar;105:198-209. doi: 10.1016/j.phrs.2016.01.030. Epub 2016 Feb 2.
PMID: 26836888
citation: Alam MA, Rahman MM. Mitochondrial dysfunction in obesity: potential benefit and mechanism of Co-enzyme Q10 supplementation in metabolic syndrome. J Diabetes Metab Disord. 2014 May 23;13:60. doi: 10.1186/2251-6581-13-60. eCollection 2014.
PMID: 24932457
citation: Stahli A, Imber JC, Raptis E, Salvi GE, Eick S, Sculean A. Effect of enamel matrix derivative on wound healing following gingival recession coverage using the modified coronally advanced tunnel and subepithelial connective tissue graft: a randomised, controlled, clinical study. Clin Oral Investig. 2020 Feb;24(2):1043-1051. doi: 10.1007/s00784-019-03008-6. Epub 2019 Jul 9.
PMID: 31290017
responsible party type: Sponsor
mesh term: Gingival Recession
mesh term: Coenzyme Q10
sharing ipd: No
ipd description: Upon request the individual participant data will be shared